This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Nuclear receptor-interacting protein 1.
Positive regulator of the circadian clock gene expression: stimulates transcription of ARNTL/BMAL1, CLOCK and CRY1 by acting as a coactivator for RORA and RORC. .
Human | |
---|---|
Gene Name: | NRIP1 |
Uniprot: | P48552 |
Entrez: | 8204 |
Belongs to: |
---|
No superfamily |
10RIP140Receptor-interacting protein 140; FLJ77253; nuclear receptor interacting protein 1; nuclear receptor-interacting protein 1; receptor interacting protein 140
Mass (kDA):
126.942 kDA
Human | |
---|---|
Location: | 21q11.2-q21.1 |
Sequence: | 21; NC_000021.9 (14961235..15065903, complement) |
Nucleus. Localized to discrete foci and redistributes to larger nuclear domains upon binding to ligand-bound NR3C1.
When acquiring an antibody to the NRIP1 marker, it is essential to know how to validate it. Boster will validate your antibody on a variety of platforms using known positive and negative samples. This will help you decide the best use of your antibody. Boster will also reward you with credits for being the first to review their product. All researchers worldwide will be able to benefit from this program.
The Anti-RIP140/NRIP1 Markers are available from various sources. In this article, we review two sources of the marker. We reviewed the literature first. This review focuses primarily upon the literature on the RIP140 genome. RIP140 is a transcriptional co-regulator and controls several transcription factors. It plays important physiological roles. The RIP140 gene plays important roles in energy expenditure and mammary gland development. It also regulates intestinal homeostasis as well as oncogenic signaling pathways. It has been linked with the development and progression of solid tumors. Survival can be predicted by the expression of RIP140 gene during chronic lymphocyticleukemia.
The Boster Bio Anti-RIP140/NRIP1 Markers are available for research purposes. This antibody reacts with Human, Mouse, and Rat. It can be stored at -20degC for six months. This product contains 5mg BSA/peptides. It can be used in research and development. There are many different ways to use anti RIP140/NRIP1 antibodies for protein expression analysis.
In vitro studies showed that BMS493, a pan-RAR antagonist, strongly inhibits NRIP1 expression within the nephric tube. This pan RAR antagonist reduced NRIP1 expression. However, RA induced an increased expression of NRIP1.
NRIP1's frame-shift mutation causes premature stop codons. It segregates in heterozygous ways in the affected individuals but is absent in seven of its unaffected family members. Individual II1 was therefore deemed an inconclusive. The red circles represent the WES analyses performed on those individuals. This condition can manifest in infancy after a positive pregnancy ultrasound screening.
The NRIP1/MIR99AHG Fusion gene is a novel biomarker that has diagnostic and pathogenic implications in AML. The NRIP1 gene is the source of the fusion and it contains three exons. Out of 806 AML-related patients, nine AML patients tested positive for the NRIP1 genes in the present study. These patients were divided into three categories: AMLCG (two), Beat AML (45) and CMML (one).
The miR-140-3p-mediated regulatory network contains over-represented DO and GO biological process terms. The miR-140-3p marker is upregulated in both TS and ASD. Its target genes play a role in synaptic and immune plasticity, chromatin binding, and immune response. With the miR140-3p marker, functional analyses have been performed on several subjects. These analyses are summarized below.
Although the NRIP1 gene is circular, its expression pattern is not linear. The two gene variants can be used in a clinical trial to distinguish pre-eclamptic and non-pre-eclamptic pregnancies. The NRIP1 gene was also found to be more prevalent in pre-eclamptic than normal pregnancies. Further research is needed in order to determine the role NRIP1 has in the etiology for pregnancies.
NRIP1 is a gene that has multiple molecular purposes. It acts as a transcription coregulator to induce hormone-controlled gene suppression. NRIP1 controls female fertility in the ovary, promotes ovulation, maintains energy homeostasis in metabolic tissues, and regulates mammary gland development. It is also found in the brain. NRIP1 plays a significant role in cognitive, emotional and other processes.
AP1 may target the NRIP1 genes. We performed transient transfection experiments using the MCF7 cell-line. We compared luciferase aactivity of constructs containing a consensus AP-1 binder site to that of NRIP1 promoter. Both promoters were upregulated, however the activity was centered within the proximal regions.
We analyzed a RNA-sequencing database to find fusion partners. NRIP1 expression was compared to a group of negative controls. We found that the NRIP1 gene was fusion-related with the open reading frame C21orf34. The fusion occurred around 21q21, approximately 1MB apart, and downstream of miR125b-2. The presence of the NRIP1 genes was also confirmed by RNA-sequencing three samples taken from cytogenetically healthy patients. The pathogenesis of leukemia may be influenced by the NRIP1 gene, we concluded.
STAD is a leading cause of cancer death worldwide. However, we do not know the molecular mechanisms that drive tumorigenesis. It is crucial to create a biomarker for STAD diagnosis. It also plays a key role in the regulation of the immune response. It regulates M1 macrophages, while suppressing M2 macrophages. Inflammation is another area of its role. The NRIP1 Gene regulates the production and use of RA.
In addition to being associated with human cancer, NRIP1 has been identified as a potential target for future breast cancer therapy. Its expression in breast cancer cells is linked to the existence of estrogen receptors. It may also play a part in the regulation PGR and ESR. It has been implicated in the regulation and transcription of CCND1. Further research is needed to understand the role NRIP1 may play in breast cancer.
The RIP140 genes is expressed in hematopoietic and other cells. It is located at 21st chromosome. It is controlled by two promoters. There are several exons. The final one covers the entire coding sequence. It is a versatile genetic marker with many applications in cell biology. Read on to learn more.
There are several hematological conditions that the RIP140 gene may be expressed, including acute meeloid leukemia (AML), in which RIP140 is significantly increased. AML is characterized a abnormal chromosome 21 as well as a complex karyotype. RIP140 levels are decreased in acute promyelocytic lung cancer. Further research is needed on the role of RIP140 and cancer biology.
Boster Bio makes antibodies that target NRIP1 and other genes. Their antibodies have a high level of specificity and affinity. They are validated using both positive and negative samples. They also provide product credits for the first users of these antibodies. They are available to scientists all over the globe. They are available online for research. This article discusses the best uses and peptides of the NRIP1 genes.
The NRIP1 marker codes for nuclear receptor-interacting Protein 140 (NRIP140). This gene regulates transcription, including that of the estrogen receptor. It also modulates lipid metabolism and mitochondrial uncoupling. It is involved a number of genomic translocations. It is not yet known if it plays any role with leukemia pathogenesis. This article provides a brief overview of NRIP1 genes and their uses.
This gene plays a critical role in CLL progression. A variety of stromal-associated genes were identified in CLL patients through gene expression profiling. One of these genes, RIP140 is an estrogen receptor binding proteins and a partner of many transcription factors as well as major oncogenic signaling pathway. It is not yet known if RIP140 has any impact on CLL biology.
PMID: 7641693 by Cavailles V., et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor.
PMID: 9556573 by Yan Z.H., et al. Regulation of peroxisome proliferator-activated receptor alpha- induced transactivation by the nuclear orphan receptor TAK1/TR4.